How to Verify TB-500 (Thymosin Beta-4) Purity and Batch Documentation
A research-use guide to verifying TB-500 (Thymosin Beta-4) purity and batch documentation, covering identity, analytical methods, and what the published and registered literature does and does not establish.
TB-500 is the common research designation for a synthetic 17–23 fragment of thymosin beta-4 (Tβ4), a naturally occurring actin-binding peptide. Synonyms encountered in the literature and in catalogue listings include thymosin beta-4 fragment 17-23, Tβ4 17-23, and synthetic thymosin beta-4; the full-length recombinant protein is a distinct material and is registered under separate investigational product names. The evidence block supplied for this page does not give a sequence, molecular formula, or molecular weight for the fragment, so none is stated here. Identity verification therefore rests on the supplier's certificate of analysis and on the analytical methods that certificate reports, not on figures reproduced from this page.
The mechanistic work around this peptide centres on the actin-sequestering activity of the thymosin beta-4 family and on downstream effects on cell migration, vascular function, and inflammatory signalling, which is the pathway context in which the registered clinical programmes described below were designed.
Research Studies
TB-500 and cardiovascular biomarkers in stable ASCVD
A Phase 1/2 trial record describes evaluation of TB-500, characterised as a 17-23 fragment of thymosin beta 4, against placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD). Safety and tolerability were the primary objectives, with exploratory endpoints assessing vascular function and inflammation biomarkers [1]. This is a registered trial record rather than a published result, and it is the only entry in the evidence block that addresses the 17-23 fragment specifically in a human population.
Thymosin beta-4 and infarct size after STEMI
A Phase IIc record describes recombinant human thymosin beta 4 injection (NL005) in patients who had sustained ST-segment elevation myocardial infarction (STEMI) and had been treated with emergency percutaneous coronary intervention (PCI). The stated questions concern whether NL005 reduces the size of permanent heart muscle damage as measured by cardiac magnetic resonance (CMR) at 90 days, and what medical problems participants experienced; two dose levels were compared [3]. The material under investigation in that record is the recombinant full-length protein, not the 17-23 fragment.
Thymosin beta-4 dose-ranging in acute myocardial infarction
Two further registered trials used multicentre randomised double-blind placebo-controlled parallel designs in acute myocardial infarction patients following PCI. One assigned 90 participants 1:1:1 to placebo, 0.5 µg/kg, or 1.0 µg/kg, with intravenous administration within 12 hours and on days 2 to 7 after PCI and observation to 90 days [5]. The other assigned 60 participants 1:1:1:1 to 0.25 µg/kg, 0.5 µg/kg, 2.0 µg/kg, or placebo, dosed intravenously on days 2 to 7 at 12 hours and 4 hours after PCI, with the same 90-day observation window [6]. Both are records of design and intent; the evidence block does not supply their outcomes.
RGN-352 and tolerability in acute myocardial infarction
An earlier registered study evaluated safety and tolerability of two active doses of RGN-352 (thymosin beta 4 injectable solution) in acute myocardial infarction patients receiving PCI angioplasty with or without stent placement. Approximately 75 subjects were to be randomised to 1200 mg, 450 mg, or placebo, given by intravenous push daily for the first three consecutive days and weekly for four further weeks [7]. As with the records above, the evidence block reports the design and not a result.
Thymosin beta-4 fragments in ophthalmic models
Two registered ophthalmic trials concern RGN-259 ophthalmic solution rather than a systemic presentation. One compares RGN-259 to placebo for the treatment of neurotrophic keratopathy [4]; the other compares RGN-259 ophthalmic solution to placebo for the signs and symptoms of dry eye [8]. These records establish that a thymosin beta-4-derived ophthalmic formulation has been taken into registered human study in ocular surface disease; they do not report comparative purity or batch data for research-grade material.
TB-500 in musculoskeletal and tendon models
A scoping review summarised existing peer-reviewed data on six emerging peptides, including thymosin beta-4 or TB-500, for musculoskeletal recovery and enhancement in animal and human models, noting that these peptides are often perceived as low risk despite the absence of efficacy or safety data for many of them [2]. Separately, a rat study evaluated BPC-157, synthetic thymosin beta-4 (TB-500), and their combination on Achilles tendon healing using biomechanical, histopathological, histochemical, and immunohistochemical analyses in male Sprague-Dawley rats [9]. The tendon findings are animal-only.
TB-500 in regenerative medicine reviews
A narrative review of regenerative peptides relevant to chronic pain management covered collagen peptides, BPC-157, thymosin beta-4, TB-500, and GHK-Cu among others [10]. Reviews of this type aggregate and contextualise prior work; they are not primary purity or identity data, and they are cited here only to indicate where TB-500 sits in the wider regenerative-peptide literature.
TB-500 and analytical detection in blood matrices
An analytical workflow paper reported a fast, streamlined, harmonised method for detecting 54 prohibited substances, including small peptides, in dried and liquid blood matrices, developed in part because earlier dried-blood-spot peptide methods required multiple preparation steps and were labour-intensive and costly [11]. This is method-development work on detection, not on the purity of supplied material, but it is the closest thing in the evidence block to an analytical-chemistry treatment of small peptides in biological matrices.
Thymosin beta-4 in in vitro corneal models
An in vitro study using electric cell-substrate impedance sensing examined the effects of ciprofloxacin on corneal epithelial cells. Mechanistic investigation into thymosin beta-4 as an adjunct to ciprofloxacin in Pseudomonas aeruginosa keratitis revealed off-target effects of the antibiotic, which prompted the in vitro work [12]. The observations are cell-culture findings and are not transferable to whole-organism outcomes.
What a batch record should let you check
Purity and identity are separate questions, and a certificate of analysis that answers only one of them is incomplete. The table below sets out the distinction as it applies to a research peptide.
| Question | What it establishes | What it does not establish |
|---|---|---|
| Identity (sequence or mass confirmation) | That the material is the intended peptide species | That the batch is free of related impurities |
| Purity by chromatographic method | Relative abundance of the main peak under stated conditions | Absolute content, or absence of co-eluting species |
| Counter-ion and water content | Mass balance of the delivered solid | Biological activity of any kind |
| Batch or lot number | Traceability to a manufacturing record | That the record has been independently audited |
Where the evidence block is silent, this page is silent. It does not supply a purity specification, a storage condition, a solubility figure, or a stability claim for TB-500, and none should be inferred from the trial records cited above, which concern formulated investigational products rather than research-grade powder.
If you are reading this for personal health reasons
This material is sold for laboratory research only, and we do not provide dosing or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation for human use.
Sources
- [1] TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD — https://clinicaltrials.gov/study/NCT07487363
- [2] Peptide Supplements and Their Therapeutic Applications in Sports Medicine — https://pubmed.ncbi.nlm.nih.gov/42578445/
- [3] Recombinant Human Thymosin Beta 4 for Injection (NL005) for Acute Myocardial Infarction — https://clinicaltrials.gov/study/NCT07586865
- [4] Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 — https://clinicaltrials.gov/study/NCT05555589
- [5] Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction — https://clinicaltrials.gov/study/NCT05984134
- [6] Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction — https://clinicaltrials.gov/study/NCT05485818
- [7] A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction — https://clinicaltrials.gov/study/NCT01311518
- [8] Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 — https://clinicaltrials.gov/study/NCT03937882
- [9] Effects of BPC-157 and TB-500 on Achilles tendon healing in rats — https://pubmed.ncbi.nlm.nih.gov/42542926/
- [10] Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management — https://pubmed.ncbi.nlm.nih.gov/42635865/
- [11] Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices — https://pubmed.ncbi.nlm.nih.gov/42328738/
- [12] Understanding the effects of ciprofloxacin on corneal epithelial cells: a study using electric cell-substrate impedance sensing (ECIS) technology — https://europepmc.org/article/PMC/PMC13477596